The American Diabetes Association® (ADA) hailed a major national victory today when the U.S. House of Representatives passed the Build Back Better Act, including the most sweeping nationwide measure to date to limit out-of-pocket co-pays for insulin. The national co-pay cap, which ADA has aggressively promoted, would apply to Medicare beneficiaries, individuals on commercial insurance, and those covered by other group health plans.
Also Read: Treating Patients Beyond Borders – Antengene Successfully Hosted Its First R&D Day
The House-passed legislation creates an out-of-pocket co-pay limit of $35 per month for insulin. In the days before the House vote, nearly 15,000 ADA advocates contacted their representatives through the ADA’s Engagement Platform to urge support for co-pay caps and for allowing the government to negotiate drug prices with manufacturers.
Until now, the diabetes community has felt the impact of the steep rise in the average cost of insulin, the price of which nearly tripled between 2002 and 2013. As a result of high costs, one in four insulin-dependent Americans reports needing to ration their insulin. “This vote is a victory for millions of Americans facing unaffordable insulin and hope for lowering other drug costs. House leaders have taken a bold and urgent step this week,” said Lisa Murdock, Chief Advocacy Officer for the ADA.
In the run-up to House consideration of the insulin co-pay cap, the ADA led efforts around the country to advocate for co-pay caps that have been enacted in 20 states and the District of Columbia.
“These states paved the way for this week’s historic action in the House,” said Murdock. “We thank those members of the House of Representatives who supported a national insulin co-pay cap, building on the efforts of state leaders before them. Together, these leaders are working to ensure that millions of people with diabetes will be able to afford their insulin and will not have to skip doses or ration because they don’t have enough money to pay for this life-saving drug.”